BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 123 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,858,000 | +42.8% | 293,567 | -0.5% | 0.00% | 0.0% |
| Q3 2016 | $1,301,000 | +64.7% | 295,020 | +6.1% | 0.00% | +100.0% |
| Q2 2016 | $790,000 | +6.8% | 278,020 | +6.3% | 0.00% | 0.0% |
| Q1 2016 | $740,000 | -72.2% | 261,537 | +1.5% | 0.00% | -66.7% |
| Q4 2015 | $2,659,000 | -9.5% | 257,682 | +0.0% | 0.00% | -25.0% |
| Q3 2015 | $2,938,000 | -29.3% | 257,680 | -7.4% | 0.00% | -20.0% |
| Q2 2015 | $4,156,000 | +102.6% | 278,397 | +22.6% | 0.01% | +66.7% |
| Q1 2015 | $2,051,000 | -24.8% | 227,135 | +1.2% | 0.00% | -25.0% |
| Q4 2014 | $2,728,000 | +23.1% | 224,364 | -1.0% | 0.00% | +33.3% |
| Q3 2014 | $2,216,000 | -22.6% | 226,575 | +0.9% | 0.00% | -25.0% |
| Q2 2014 | $2,863,000 | – | 224,551 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |